Home/Pipeline/MDMA-assisted therapy

MDMA-assisted therapy

Post-Traumatic Stress Disorder (PTSD)

Phase 3Active

Key Facts

Indication

Post-Traumatic Stress Disorder (PTSD)

Phase

Phase 3

Status

Active

Company

Lykos Therapeutics

About Lykos Therapeutics

Lykos Therapeutics is a clinical-stage biotech company pioneering the development of MDMA-assisted therapy for PTSD, positioning it as a potential first-in-class treatment in the psychedelics sector. Operating as a public benefit corporation, the company balances therapeutic development with a stated commitment to social impact. Its lead program has completed Phase 3 trials and is under FDA review, representing one of the most advanced psychedelic drug development programs globally. The company is also exploring broader applications of its therapeutic model for other mental health conditions.

View full company profile

Therapeutic Areas

Psychiatry Mental Health Post-Traumatic Stress Disorder

Other Post-Traumatic Stress Disorder (PTSD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
PES200	Virpax Pharmaceuticals	Discovery/Preclinical	Active
Sequential Dialysis Technique	Halberd	Discovery	Active Research (Gov't Funding Sought)
NeuroDirect™ Ketamine	Psycheceutical Bioscience	Phase 1	Active
Sana Device for PTSD	Sana Health	Pilot/Proof-of-Concept	Active
Neuroplastogen Programs	Delix Therapeutics	Pre-clinical	Active
TSND-201 (Methylone)	Transcend Therapeutics	Phase 2	Active
Phoenix CR	Evren Technologies	Unknown	Active
Lu AG09222	Lundbeck	Phase 2	Active
COMP360 Psilocybin Therapy	Compass Pathways	Phase 2	Active
NRX-101	NRx Pharmaceuticals	Phase 2	Investigational
Ketamir-2 (Ketamir)	MIRA Pharmaceuticals	Phase 1	Active